Free Medical Billing Audit

Specialty billing

Dermatology Billing Services: Biopsies, Mohs, Modifiers, and Biologics

Dermatology billing services cover a specialty where one visit can contain a medical evaluation, a biopsy, a destruction procedure, and a cosmetic request, each with different payment rules. Getting it right depends on separating medical from cosmetic care, choosing the right biopsy, excision, or destruction code, and supporting modifiers 25 and 59. Mednex Group supports dermatology practices with claim preparation and follow-up as defined process, and cannot guarantee payer decisions or reimbursement.

Calm consultation room with a seated person
On this page
  1. What dermatology billing involves
  2. Who dermatology billing problems affect
  3. Medical versus cosmetic: where the line falls
  4. Biopsy coding: technique, count, and the pathology claim
  5. Excision and destruction coding
  6. Excision of benign and malignant lesions
  7. Destruction of premalignant and benign lesions
  8. Mohs surgery billing
  9. Modifier 25, modifier 59, and the NCCI edits
  10. Modifier 25 on the evaluation
  11. Modifier 59 and X modifiers on procedures
  12. Prior authorization for biologics, phototherapy, and procedures
  13. Skin check frequency and diagnosis support
  14. What goes wrong: denial patterns and fixes
  15. Hypothetical example: one visit, three lines
  16. Documentation and records checklist
  17. How progress is measured
  18. What Mednex handles and what your practice handles
  19. Related services and next steps

What dermatology billing involves

Dermatology practices bill several kinds of work in a single clinic day: medical dermatology for conditions such as psoriasis, eczema, acne, and skin infections; surgical dermatology for biopsies, excisions, destruction, and Mohs surgery; dermatopathology when the practice reads its own slides; and cosmetic services that insurance does not pay for. Each has a different documentation standard and a different payer view.

The result is a coding workload with heavy procedure volume and thin margins per code. A missed modifier, a wrong lesion count, or a diagnosis that does not match a destruction code will not make headlines, but across thousands of claims it adds up to real revenue leakage. Dermatology billing services focus on those details: lesion-level documentation, code selection, modifier logic, pathology matching, and follow-up on denials. For the full revenue cycle context, see the medical billing overview.

Who dermatology billing problems affect

  • General dermatology practices with high volume procedure days
  • Practices with in-house Mohs surgeons and dermatopathology labs
  • Combined medical and cosmetic practices that sell aesthetic services
  • Practices that prescribe and administer biologics for psoriasis, atopic dermatitis, and similar conditions
  • Groups with a mix of physicians, PAs, and nurse practitioners where incident-to and supervision rules matter
  • New practices still waiting on payer enrollment (see medical credentialing services)

Medical versus cosmetic: where the line falls

The medical versus cosmetic distinction drives whether the insurance plan pays or the patient does. Medical services treat a disease, symptom, or functional problem. Cosmetic services improve appearance without treating a medical condition, and most plans, including Medicare, exclude them. Some services sit in a gray zone: removing a lesion that is irritated or changing, treating scarring after disease, or treating a condition that has both appearance and symptom components.

A defensible approach:

  1. Decide at scheduling or check-in. If the patient asks for cosmetic care, say so and quote the self-pay fee before the service.
  2. Document the medical reason. For a lesion removed as medical, the note should show symptoms (bleeding, pain, irritation, rapid change), the clinical assessment, and the plan. The reason should be in the chart before the claim, not added after a denial.
  3. Keep the two on separate lines. When a visit includes medical and cosmetic work, bill each correctly and give the patient a clear statement.
  4. Use the payer’s rules for non-covered services. For Medicare patients, a notice process applies for services expected to be denied, and a specific modifier identifies services that are statutorily excluded. Confirm the current requirements with your Medicare Administrative Contractor.

Routine skin checks add a related question. A full-body skin examination for a patient with no complaint or history is a screening service, and coverage varies. Original Medicare does not generally cover routine skin screening without a sign, symptom, or qualifying history, while some commercial plans cover it as a preventive service. Verify the plan, and code to the facts: a screening encounter and a problem-focused visit for a known condition are different encounters with different diagnoses.

Biopsy coding: technique, count, and the pathology claim

Skin biopsy codes are selected by technique, not by lesion size. The main families are tangential (shave) biopsy, punch biopsy, and incisional biopsy. Each family has a code for the first lesion and an add-on code for each additional lesion, which makes the lesion count and technique the two facts the coder needs. The codes are 11102 and 11103 for tangential, 11104 and 11105 for punch, and 11106 and 11107 for incisional biopsy.

Technique First lesion Each additional lesion Documentation to look for
Tangential (shave) biopsy 11102 +11103 Site, technique, number of lesions, specimen sent to pathology
Punch biopsy 11104 +11105 Punch size and site; closure is included
Incisional biopsy 11106 +11107 Wedge or partial removal, with the intent to sample

The point to watch is the difference between a biopsy and a removal. A shave removal of a benign lesion is reported with a different family (shave removal codes, selected by lesion size and site). A biopsy that is meant to sample tissue and a removal that is meant to take the lesion off are not the same service, and the note should say which was done. Another pattern to watch is a biopsy followed by a definitive treatment of the same lesion on the same day, which can bundle depending on the payer and the intent recorded in the note.

Pathology is a separate claim. If the practice owns the lab and reads the slides, it bills the pathology service, commonly 88305 for a skin biopsy, and carries the CLIA certificate that goes with it. If an outside lab reads them, it bills the lab service and the practice does not. Mixing up who bills for pathology is a common cause of duplicate claims or missing revenue. Many payers also require that labs be in network, so verify before choosing where specimens go.

Excision and destruction coding

Excision of benign and malignant lesions

Excision codes depend on whether the lesion is benign or malignant, the anatomic site, and the excised diameter. For excisions the measured diameter includes the lesion plus the narrowest margins, not the lesion alone. Benign lesion excisions are in the 11400 series, malignant excisions are in the 11600 series, and each series is further divided by body area. Repair of the wound (simple, intermediate, or complex) may be reported separately only when the repair is more than simple and meets the code definitions. The record should show the measured lesion, margins, excised diameter, and the repair method.

A key rule: you may not know whether a lesion is malignant when it is removed. Many payers want the malignant excision code reported only after pathology confirms malignancy, which means holding the claim until the report is in hand. A claim sent early with a benign code may need correction later. Set a hold rule so these charges wait for pathology.

Destruction of premalignant and benign lesions

Destruction of premalignant lesions such as actinic keratoses uses 17000 for the first lesion, 17003 for the second through fourteenth, and 17004 for fifteen or more. Destruction of benign lesions such as warts and molluscum, other than skin tags and cutaneous vascular lesions, uses 17110 for up to fourteen lesions and 17111 for fifteen or more. Destruction of malignant lesions uses the 17260 to 17286 family by site and size.

These are counting codes, so lesion-level documentation is the whole claim. Notes that say “multiple AKs treated with liquid nitrogen” with no count or locations will not hold up. Notes that state the number of lesions and the body sites are strong. Also check that the diagnosis supports the code: premalignant destruction needs a premalignant diagnosis, and a wart code needs a wart diagnosis. A mismatch is a common automated edit.

Mohs surgery billing

Mohs micrographic surgery is reported by stage and by site. 17311 is the first stage for the head, neck, hands, feet, genitalia, or any site involving muscle, cartilage, bone, tendon, major nerves, or vessels, covering up to five tissue blocks. 17312 is each additional stage for those sites. 17313 is the first stage for the trunk, arms, or legs, and 17314 is each additional stage there. 17315 is an add-on for each tissue block beyond the first five in any stage.

The key structural facts:

  • The codes include gross tumor removal, tissue mapping, microscopic examination by the surgeon, and routine staining. The surgeon acts as both surgeon and pathologist for the codes to apply.
  • If another physician reads the slides and bills for it, the Mohs codes are not the correct choice.
  • The record must document the indication, the site and size, the number of stages, the number of blocks per stage, and the margin status after each stage.
  • Reconstruction or repair after Mohs is separate and is coded by repair type. When a different physician performs the repair, the claims and documentation need to show that.
  • Payers apply appropriate use criteria, so the diagnosis, site, and tumor characteristics need to meet the plan’s medical policy.

Review Mohs claims for stage count against the operative record, block counts against the map, and the site category (first-stage code for head and neck versus trunk). One mismatch between the map and the claim is enough to draw a request for records.

Modifier 25, modifier 59, and the NCCI edits

Dermatology uses modifiers more than most specialties because medical evaluation and procedures often share a visit.

Modifier 25 on the evaluation

Modifier 25 marks an evaluation and management service that is significant and separately identifiable from the procedure performed the same day. A patient who comes in for a rash and has an unrelated suspicious mole biopsied supports an E/M plus a biopsy. A patient who comes in to have a known lesion destroyed and is simply checked in before the treatment typically does not. The note needs a separate chief complaint or problem, a history and exam relevant to it, and an assessment and plan that is distinct from the procedure decision. Payers monitor modifier 25 rates by provider, so applying it to every visit is a risk. See medical billing modifiers for the general rule.

Modifier 59 and X modifiers on procedures

Modifier 59 indicates a distinct procedural service, such as a separate site, lesion, or session, when two codes would otherwise be bundled under the National Correct Coding Initiative edits. Some payers prefer the more specific X modifiers: XE for a separate encounter, XS for a separate structure or organ, XP for a separate practitioner, and XU for an unusual non-overlapping service. Use them only when the record shows that the services were truly distinct, for example destruction of an actinic keratosis on the forearm and biopsy of a different lesion on the back. Never use a modifier only to get past an edit. For the concept behind these edits, see what is unbundling in medical billing.

A lesion-level habit that prevents most modifier denials

Have the clinician record each procedure with its site, lesion number, technique, and diagnosis at the point of care. A coder can then apply modifiers from facts in the note. Reconstructing the visit from memory days later is how mismatches happen.

Prior authorization for biologics, phototherapy, and procedures

Dermatology prior authorization is mostly about drugs. Biologics and other advanced therapies for psoriasis, atopic dermatitis, hidradenitis suppurativa, and similar conditions usually require authorization, and many go through the pharmacy benefit and a specialty pharmacy instead of being billed by the office. Whether the office buys and bills the drug or the patient receives it through pharmacy is set by the plan, and that choice changes the paperwork, the payment path, and the financial risk to the practice.

Plans often ask for:

  • Confirmed diagnosis and disease severity measures used in the plan’s policy, such as affected body surface area or a standard severity score
  • History of prior treatments tried, including topical agents, phototherapy, or conventional systemic drugs, with dates and outcomes
  • Prescriber specialty and the monitoring plan
  • Reauthorization at set intervals with response documentation

Other dermatology services may also require approval, such as phototherapy courses, certain Mohs cases, or some excisions. Track each request, the approved item and quantity, and the end date. The workflow described on the prior authorization services page applies directly. An approval does not guarantee payment, and a pharmacy benefit denial is handled through a different appeal channel than a medical claim denial.

Skin check frequency and diagnosis support

Payers often limit how frequently certain services are covered, and dermatology is full of repeat visits: skin checks for patients with a history of skin cancer, follow-up for actinic keratoses, and treatment series for warts. Diagnosis coding has to show why the visit was needed.

  • For patients with a personal history of skin cancer, document the history and the reason for surveillance. A history diagnosis alone may not be accepted as a reason for an E/M by every payer.
  • Screening encounters and problem visits should use different diagnosis logic. A screening claim with problem-based codes, or the reverse, is an audit finding.
  • Repeat destruction of the same lesion within a short window can be questioned. Record why it persisted or recurred.
  • Use the highest specificity the record supports, including laterality and site where the code set allows.

What goes wrong: denial patterns and fixes

Problem Evidence to inspect Likely cause Corrective action
E/M bundled into procedure Modifier 25 and visit note No separate problem documented Resubmit with support if distinct; otherwise accept the bundle
Destruction denied Diagnosis, lesion count, site Diagnosis does not match premalignant or benign family Correct diagnosis from the record; add count and site
Excision paid as benign after malignant path Pathology report date versus claim date Claim sent before pathology returned Submit a corrected claim with the final diagnosis
Biopsy and removal bundled Intent and sequence in the note Same lesion biopsied and removed Verify intent; separate lesions can use distinct modifiers
Mohs stage mismatch Map, operative note, claim Stage or block count differs from record Correct to the record before payer review
Pathology duplicate or missing Lab ownership and billing entity Wrong party billed the service Confirm who reads the slides and rebill accordingly
Biologic claim denied Authorization, benefit type, drug code and units Wrong benefit path or units Verify benefit type and resubmit or appeal with documentation

For a method to trace these patterns to their source, see denial management services and the explainer why are medical claims denied.

Hypothetical example: one visit, three lines

Hypothetical example. All details are invented and round. A patient is seen for a rash that has been present for several weeks. During the visit the clinician also notices an irregular lesion on the back and takes a punch biopsy, then treats three actinic keratoses on the forearm with liquid nitrogen. A correct claim has an E/M for the rash with modifier 25, a punch biopsy line, and a premalignant destruction line for three lesions. If the note records only “rash, biopsy, AKs treated,” the coder cannot choose between lesion counts or confirm that the E/M was separate. If the note records the rash assessment and plan, the biopsy site and technique, and the three forearm lesions, each line can be supported. The difference is not billing skill. It is what the clinician captured at the time of care.

Documentation and records checklist

  • Visit note with separate assessment for each problem addressed
  • Procedure note listing site, lesion number, technique, size, and closure or repair
  • Lesion count for destruction codes, with sites
  • Pathology request, report, and date received
  • Mohs map, stage and block counts, margin status
  • Photos for medical necessity where the practice and payer use them
  • Authorization and drug records: product, units, lot, and discarded amount if any
  • Cosmetic consent and fee quote when applicable

The medical billing audit checklist shows how to turn a list like this into a routine review.

How progress is measured

  • Denial rate by service line (E/M, biopsy, destruction, excision, Mohs, pathology, drugs)
  • Modifier 25 rate by provider compared with documented separate problems
  • Charges held pending pathology and the time to release
  • A/R aging by payer and the share over 90 days (see how to reduce A/R over 90 days)
  • Authorization requests started before drug administration
  • Cosmetic and non-covered balances collected before or at service

Mednex reports on these measures with your own data and does not publish outcome numbers, since results depend on your starting point and payer mix.

What Mednex handles and what your practice handles

Mednex process responsibilities Practice responsibilities
Coding review against supplied notes, modifier checks, and claim submission Clinical assessment, procedure documentation, and diagnosis decisions
Pathology hold rules and charge release workflow Pathology orders, results, and lab selection
Prior authorization tracking and denial follow-up Clinical answers on authorization forms and prescriber attestations
Payment posting, A/R follow-up, and reporting Fee schedules, cosmetic pricing, and patient consent

The access method, security setup, and any business associate agreement are settled in writing before work starts. For the broader process, see revenue cycle management.

Skin practices often share patterns with procedural specialties. See urology billing for office procedure and pathology workflows, and the full list of specialty billing pages.

A practical first step is the Free Medical Billing Audit. You supply report exports such as an A/R aging, a denial or remittance report, and a payer list. Do not send patient records through the website. Protected health information is shared only through a secure workflow under a signed business associate agreement. To ask questions first, use the contact page.

Frequently asked questions

What do dermatology billing services include?

Dermatology billing services include coding review of visits and procedures, modifier checks, claim submission, pathology matching, payment posting, prior authorization tracking, denial follow-up, and A/R reporting. They also help keep medical care separate from cosmetic care so patients are billed correctly and given self-pay quotes when insurance does not apply. The practice stays responsible for clinical documentation, diagnoses, and the choice of treatment, because billing can only reflect what the chart says. Ask what is included, such as appeals and biologic authorizations, and get the scope in writing before comparing vendors.

How do you tell medical dermatology from cosmetic for billing?

Medical care treats a disease, symptom, or functional problem, and the note should show it, such as bleeding, pain, irritation, or rapid change in a lesion. Cosmetic care improves appearance and is usually excluded by insurance. Decide at scheduling, document the medical reason before billing, and give patients a self-pay quote before any cosmetic work is done. Some visits are mixed, for example a medically necessary removal that also improves appearance, and the note should explain the medical reason. For Medicare patients, follow the notice and modifier rules your contractor publishes, and keep the decision in a written office policy so every patient is handled the same way.

When can a dermatologist bill an E/M with a procedure on the same day?

A dermatologist can bill both when the evaluation is significant and separately identifiable from the procedure, usually by adding modifier 25 to the evaluation and management code. A separate complaint, such as a rash evaluated on the same day as a biopsy of an unrelated lesion, supports it. A brief check before a planned treatment generally does not. The note should show a distinct history, exam, and plan for the separate problem, since payers monitor modifier 25 rates. Training providers to document the separate problem in its own assessment line removes most disputes at the coding stage and makes an appeal easier if one is needed.

How are skin biopsies coded?

Biopsies are coded by technique and count: tangential (shave), punch, or incisional, each with a code for the first lesion and an add-on code for every additional lesion. The note must say which technique was used, the site, and the number of lesions. Pathology is a separate claim, billed by whichever party reads the slides. A biopsy meant to sample tissue differs from a removal meant to take the lesion off, so the intent should be clear in the note. Hold charges for lesions that may be malignant until the pathology report arrives, so the claim carries the final diagnosis instead of a symptom.

How is Mohs surgery billed?

Mohs codes are chosen by site and stage. The first stage uses 17311 for the head, neck, hands, feet, and genitalia, or 17313 for the trunk, arms, and legs. Later stages use 17312 or 17314, and 17315 covers extra tissue blocks beyond the first five in a stage. The same physician must act as both surgeon and pathologist for these codes. Repairs are coded separately, and payers apply their own medical policy criteria for when Mohs is appropriate. Reviewing the operative map against the claim before submission catches stage and block mismatches early, and check each payer's current policy for site and size criteria.

Why are destruction claims denied?

Common causes are a diagnosis that does not match the code family, such as a premalignant destruction code billed without a premalignant diagnosis, and notes that give no lesion count or sites. Some payers also question repeat treatment of the same lesion in a short window. Count lesions at the point of care, record the sites, and match the diagnosis before submitting the claim. Repeat treatment of the same lesion should carry a reason in the note, such as persistence or recurrence, so a reviewer can see why it was needed. Review denials by cause across many claims to spot a pattern in one provider's notes.

Do biologics for psoriasis or eczema need prior authorization?

Usually, yes. Plans commonly ask for the diagnosis, a severity measure, and a history of prior treatments such as topical therapy or phototherapy, then require reauthorization at set intervals. Many biologics go through the pharmacy benefit and a specialty pharmacy rather than being billed by the office, so check which path the patient's plan uses before you order. Approval does not guarantee payment, since eligibility on the date of service still applies. Calendar reauthorization dates and keep the approval reference with the order, because a lapse can interrupt therapy and payment at the same time.

Are routine skin checks covered by insurance?

It depends on the plan. Original Medicare generally does not cover routine skin screening without a sign, symptom, or qualifying history, while some commercial plans cover screening as a preventive service. Verify the benefit before the visit, because frequency limits and cost sharing differ. Code the encounter as what it was: a screening visit and a visit for a known condition use different diagnosis logic, and a screening that turns into a problem-focused visit needs notes that show the change. Check the plan's preventive benefit list or ask the payer, and tell the patient before the visit what they may owe.

Can a small dermatology practice use a billing company?

Yes. Small practices often have one coder handling every procedure, pathology report, and authorization, which leaves little room for follow-up on denials. A billing partner can take on defined parts, such as denial follow-up or authorization tracking, or the full cycle. Compare scope, access method, reporting, and fees in writing, and ask how modifiers and pathology holds are handled. A short initial scope, such as denial follow-up only, is a reasonable way to test the fit before committing more work. Mednex can review your A/R and denial reports first through the free audit, with no obligation.

How is dermatology billing priced?

Pricing depends on claim volume, which tasks are included, and your payer mix. Mednex does not publish rates on this page, and the model for your practice is set in a written scope. Ask any vendor for the pricing model in writing, including what counts as extra, how it scales with volume, and how appeals, older claims, and prior authorization work are treated. Also ask who owns the data, how reports are delivered, and what happens at the end of the agreement, so you can leave with your records and reports intact if the arrangement does not work out.

Sources

Payer rules vary by payer, plan, state and contract. Check the current policy before acting.

See where your revenue cycle stands

Request the free medical billing audit. You receive a written summary of findings and a walkthrough call. No obligation, and no patient information is needed to start.

Do not include patient names, insurance IDs or clinical details. If records are needed later, we set up a secure way to share them.